BlossomHill Therapeutics, Inc. (BLSM) EBITDA
BlossomHill Therapeutics, Inc. (BLSM) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$24.67M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$14.10M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | (m) | -$24.67M | (m) | (m) | (m) | (m) | (m) | (m) | $21.36M | (m) | (m) |
|---|
| 2025-06-30 | Reported | (m) | -$14.10M | (m) | (m) | (m) | (m) | (m) | (m) | $12.53M | (m) | (m) |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|